FDA advisers say Sanofi's MS drug Lemtrada can be approved

11/14/2013 | PharmaTimes (U.K.) · Bloomberg

An FDA advisory committee said Sanofi's Lemtrada, or alemtuzumab, was not so risky that it precluded approval as a treatment for multiple sclerosis. The drug, however, should not be used for first-line treatment, the panel said. The agency is set to issue a decision by Dec. 27.

View Full Article in:

PharmaTimes (U.K.) · Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA